{"id":943156,"date":"2026-03-10T09:27:29","date_gmt":"2026-03-10T13:27:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/"},"modified":"2026-03-10T09:27:29","modified_gmt":"2026-03-10T13:27:29","slug":"alnylam-to-webcast-ttr-investor-webinar","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/","title":{"rendered":"Alnylam to Webcast TTR Investor Webinar"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Alnylam to Webcast TTR Investor Webinar<\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=624cc8dda767551fb206426ac15fd6c2\">Alnylam Pharmaceuticals, Inc.<\/a> (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company\u2019s website, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=www.alnylam.com&amp;index=2&amp;md5=d72623a77fb0236c996f6642b77a092b\">www.alnylam.com<\/a>, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event.<\/p>\n<p>\nThe TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA<sup>\u00ae<\/sup> in ATTR-CM, will highlight Alnylam\u2019s progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability of the Company\u2019s flagship TTR franchise.<\/p>\n<p>\nThe webinar will feature Alnylam\u2019s senior commercial and medical leaders, including:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTolga Tanguler \u2013 Chief Commercial Officer<\/p>\n<\/li>\n<li>\nJohn Kennedy \u2013 SVP, TTR Franchise Global Commercialization Lead<\/p>\n<\/li>\n<li>\nMark Soued \u2013 SVP, Head of U.S. &amp; TTR Lead<\/p>\n<\/li>\n<li>\nSameer Bansilal \u2013 VP, Medical Affairs, TTR Disease Area Lead<\/p>\n<\/li>\n<\/ul>\n<p><b>About Alnylam Pharmaceuticals<br \/>\n<br \/><\/b>Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its <i>Alnylam 2030<\/i> strategy to accelerate innovation and scale impact to transform human health. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=www.alnylam.com&amp;index=3&amp;md5=9dc69e4d34250c92f95b1bdaea740c13\">www.alnylam.com<\/a> or follow Alnylam on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FAlnylam&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=54d99eecf888d06a796a2f84a8cb22a4\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Falnylam-pharmaceuticals%2F&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=f5bb7ca6bd7bd6070f10cc6b7ac5af37\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FAlnylamPharma%2F&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=8fb3807666992df72b59cebe9f69f7d2\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Falnylampharma%2F&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=b5f63d26fdd1587ee8a512f5fb5262d3\">Instagram<\/a>, or <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2F%40AlnylamPharmaceuticals&amp;esheet=54442893&amp;newsitemid=20260310495157&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=ddbcbd67dd990ad8d30a9345f0372a13\">YouTube<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260310495157\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260310495157\/en\/<\/a><\/span><\/p>\n<p><b>Alnylam Pharmaceuticals, Inc.<\/b><\/p>\n<p>\nChristine Akinc<br \/>\n<br \/>(Investors and Media)<br \/>\n<br \/>617-682-4340<\/p>\n<p>\nJosh Brodsky<br \/>\n<br \/>(Investors)<br \/>\n<br \/>617-551-8276<\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260310495157\/en\/1161817\/3\/Alnylam_Corporate_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Alnylam to Webcast TTR Investor Webinar CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company\u2019s website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA\u00ae in ATTR-CM, will highlight Alnylam\u2019s progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability of the Company\u2019s flagship TTR franchise. The webinar will feature Alnylam\u2019s senior commercial and medical leaders, including: Tolga Tanguler \u2013 Chief Commercial Officer John Kennedy &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alnylam to Webcast TTR Investor Webinar&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-943156","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alnylam to Webcast TTR Investor Webinar - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alnylam to Webcast TTR Investor Webinar - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alnylam to Webcast TTR Investor Webinar CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company\u2019s website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA\u00ae in ATTR-CM, will highlight Alnylam\u2019s progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability of the Company\u2019s flagship TTR franchise. The webinar will feature Alnylam\u2019s senior commercial and medical leaders, including: Tolga Tanguler \u2013 Chief Commercial Officer John Kennedy &hellip; Continue reading &quot;Alnylam to Webcast TTR Investor Webinar&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T13:27:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alnylam to Webcast TTR Investor Webinar\",\"datePublished\":\"2026-03-10T13:27:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/\"},\"wordCount\":320,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/\",\"name\":\"Alnylam to Webcast TTR Investor Webinar - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-03-10T13:27:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alnylam-to-webcast-ttr-investor-webinar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alnylam to Webcast TTR Investor Webinar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alnylam to Webcast TTR Investor Webinar - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/","og_locale":"en_US","og_type":"article","og_title":"Alnylam to Webcast TTR Investor Webinar - Market Newsdesk","og_description":"Alnylam to Webcast TTR Investor Webinar CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company\u2019s website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA\u00ae in ATTR-CM, will highlight Alnylam\u2019s progress in delivering for patients with ATTR-CM, as well as the long-term growth and durability of the Company\u2019s flagship TTR franchise. The webinar will feature Alnylam\u2019s senior commercial and medical leaders, including: Tolga Tanguler \u2013 Chief Commercial Officer John Kennedy &hellip; Continue reading \"Alnylam to Webcast TTR Investor Webinar\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-10T13:27:29+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alnylam to Webcast TTR Investor Webinar","datePublished":"2026-03-10T13:27:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/"},"wordCount":320,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/","name":"Alnylam to Webcast TTR Investor Webinar - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-03-10T13:27:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260310495157r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alnylam-to-webcast-ttr-investor-webinar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alnylam to Webcast TTR Investor Webinar"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=943156"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943156\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=943156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=943156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=943156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}